Results 111 to 120 of about 83,505 (263)

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Diagnosis validity of AgNOR staining for differentaing non-Hodgkin lymphoma from reactive hyperplasia

مجله دانشگاه علوم پزشکی گرگان, 2005
Background&Objective: There are different methods including H&E, imonhistochemstry, flu cytometry, AgNOR staining for differentiation reactive hyperplasia from lymphoma.
Zh.Torabizade (MD), F.Naghshvar (MD), O.Emadian (MD)   +2 more
doaj  

Cutaneous Hodgkin’s lymphoma

South Asian Journal of Cancer, 2017
Asawari Anant Ambekar, Chitralekha S Soman   +1 more
openaire   +3 more sources

Machine learning‐driven investigation on liquid–liquid phase separation‐related prognostic signature in diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive non‐Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid–liquid phase separation (LLPS)‐related prognostic model to improve risk stratification.
Zhen‐Zhong Zhou, Jia‐Chen Lu, Zhao Wang, Rong‐Hui Chen, Hai‐Long Li, Wan‐Ting Chen, Yu‐Ning Deng, Hui‐Juan Zhang, Yu Wang, Xuan‐Ye Zhang, Wei‐Juan Huang, Xiao‐Peng Tian   +11 more
wiley   +1 more source

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

British Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani, L. Milan, L. Cascione, A. Di Rocco, I. Kryachok, A. J. Davies, A. Stathis, D. Rossi, P. W. M. Johnson, M. Martelli, E. Zucca   +10 more
wiley   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Radiotherapy in the Modern Treatment of Hodgkin Lymphoma. [PDF]

Cancer J
Carmicheal J, Enke C.
europepmc   +1 more source

The Non-Hodgkin's Lymphomas [PDF]

CA: A Cancer Journal for Clinicians, 1985
J E, Ultmann, R H, Jacobs
openaire   +2 more sources

A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, EarlyView.
Early letermovir initiation (day 0) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) reduced early cytomegalovirus (CMV) infection and delayed first CMV DNAemia compared with later starts. Extending prophylaxis to 200 days virtually eliminated late CMV reactivation and improved 1‐year overall survival, with no grade ≥3 drug‐related
Shiyu Chen, Zhihang Su, Xiaohan Zhang, Xiaoqing Li, Xin Du   +4 more
wiley   +1 more source